Data Sharing Standards

Guidance for data submission standards

Providing Regulator Submissions In Electronic Format Standardized Study I

Guidance for Industry

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER

> December 2014 Electronic Submissions

TABLE OF CONTENTS

INTRODUCTION1
REQUIREMENT TO SUBMIT ELECTRONIC STANDARDIZED STUDY DATA 2
. For what submission types is an electronic submission of standardized study data required?
. What types of submissions are exempted from the electronic submission requirements for standardized study data?
. What are the requirements that must be followed for electronic submission of standardized study data?
. Will FDA issue waivers of the electronic submission requirements for standardized study data?
. When will electronic submission of standardized study data be required? 5
ADDITIONAL SUPPORT
. Meetings with FDA
. Implementation Support 10

Guidance for data submission standards

II. REQUIREMENT TO SUBMIT ELECTRONIC STANDARDIZED STUDY DATA

A. For what submission types is an electronic submission of standardized study data required?

Electronic submissions of standardized study data will be required for the following submission types:

- Certain investigational new drug applications (INDs)^{4,5}
- New drug applications (NDAs)
- Abbreviated new drug applications (ANDAs)
- Certain biologics license applications (BLAs)⁶

Epidemiological studies are now adopted this standards

This requirement also includes all subsequent submissions, including amendments, supplements, and reports to one of the submission types identified above. Study data in submissions that are not submitted electronically will not be filed, unless exempt from the electronic submission requirements or unless FDA has granted a waiver.

Sponsors and applicants must submit study data electronically using the format described in this guidance for both clinical and nonclinical studies.


Guidance for data submission standards


3. Controlled Terminology Standard

The use of controlled terminology standards, also known as vocabularies, is an important component of study data standardization and is a critical component of achieving semantically interoperable data exchange. 11 Controlled terminology standards specify the key concepts that are represented as preferred terms, definitions, synonyms, codes, and code systems. Controlled terminology standards are maintained by external organizations (i.e., external to the sponsor or applicant). Sponsor- or applicant-defined custom terms are not considered controlled terminologies. However, some controlled terminologies are extensible and permit additions to existing codelists. It is the expectation that sponsors or applicants will use the controlled terminologies maintained by external organizations as the standard. Examples of controlled terminology standards include:

- The National Drug File (NDF) Reference Terminology for drug classifications¹²
- CDISC Controlled Terminology¹³
- Medical Dictionary for Regulatory Activities (MedDRA)¹⁴

Clinical Data Interchange Standards Consortium (CDISC)





Data Standards for Sharing

Study #2 – dmg.xpt

ID	GENDER
A1	Male
A2	Male
A3	Female
A4	Female
A5	Male

demog.xpt

F

M

0001

0002

0004

0005

Study #3 - axd222.xpt

USUBID	SEX
00011	0
00012	1
00013	1
00014	0
00015	1

Study #4 - dmgph.xpt

PTID	GENDER
0001	1
0002	1
0003	2
0004	2
0005	1

CDISC Models


- Study Data Tabulation Model (SDTM)
 - Version 3.1.1 and 3.1.2 accepted by FDA
 - Referenced as specification in FDA Guidance on eSubmissions for Implementation of ICH eCommon Technical Document
- Analysis Dataset Models (ADaM)
 - ADaM Version 2.1 and Implementation Guide Version 1.0 released 12/09
 - Accepted by FDA
- Clinical Data Acquisition Standards Harmonization (CDASH)
 - recommended basic standards for the collection of clinical trial data
 - Version 1.1 released January 2011
- Operational Data Model (ODM)
 - Production Version 1.3
 - XML schema
 - Part of eCTD data specifications
- Protocol Representation Model
 - Version 1.0 released May 2009
 - Spreadsheet of protocol elements with definitions; documentation; initial HL7 model
- Laboratory Data Model (LAB)
 - Production Version 1.0.1
 - Implementations through SAS, ASCII, XML/ODM and HL7 V3 RIM message
- Standards for the Exchange of Non-clinical Data (SEND)
 - Version 2.3 released November 2005. Based upon CDISC SDS V3.1
 - Included in SDTM model now referenced in FDA Guidance



Data Sharing Models

Most observations collected during the study will be divided among three domain classes: Interventions, Events and Findings. Other information is captured in the Other/Special Purpose Domain Class.





Data Standard Modules for Sharing

Special-Purpose Domains (defined in Section 5):

Demographics — DM

Comments — CO

Subject Elements — SE

Subject Visits — SV

Interventions General Observation Class (defined in Section 6.1):

- Concomitant Medications CM
- Exposure EX

Substance Use — SU

Events General Observation Class (defined in Section 6.2):

- Adverse Events AE
- Medical History MH
- Clinical Events CE

- Disposition DS
- Protocol Deviations DV

Findings General Observation Class (defined in Section 6.3):

- ECG Test Results EG
- Laboratory Test Results LB
- Questionnaires QS
- Vital Signs VS
- Microbiology Specimen MB
- PK Concentrations PC


- Inclusion/Exclusion Criterion Not Met IE
- Physical Examination PE
- Subject Characteristics SC
- Drug Accountability DA
- Microbiology Susceptibility Test MS
- PK Parameters PP

Findings About (defined in Section 6.4)

Findings About — FA

Trial Design Domains (defined in Section 7):

Data Standard Modules for Sharing



Source: http://www.lexjansen.com/phuse/2012/is/IS04.pdf


Data Standard Modules for Sharing

2.2.2 The Events Observation Class

Table 2.2.2: Events — Topic and Qualifier Variables, One Record per Event Variable Variable Label Type Role Description Data Class Name Required Topic Variable Expected Permissible --TERM Reported Term Char Topic Topic variable for an event observation, which is the verba Relationship FIGURE 8 - EVENTS EXAMPLE No relationship variables Events Clinical Research STUDYID USUBJID --MODIFY Modified Reported Char Not submitted Term Protocol Study Site Subject Page IVO. Repeat No. Visit Nama DOMAIN = 'AE' --LLT Lowest Level Term Char Adverse Event AESEO = Derived Did the subject experience any adverse events? Not submitted Start date/ NCI CTC End date End time --LLTCD Lowest Level Term Num Adverse Event (hh:mm) Ongoing Grade Severity Code AESTDTC AETOXGR AESEV AETERM AEENRTI AEENDTC Other Action Taken Outcome Causality Action taken with Study Drug --DECOD (check all that apply) Dictionary-Derived Char AEREL AEOUT Term **AEACN** Medication given Serious Serious Criteria (check all that apply) Non-drug therapy Yes AESDTH, AESCONG, AESHOSP, Hospitalization Requires hospitalization AESDIAB, AESLIFE, AESMIE Life threatening AEACNOTH

Source: http://www.lexjansen.com/phuse/2012/is/IS04.pdf

Data Standards for Traceability



Data Standards for Submision

